NewsRoom Articles - Page 41 of 144 - PsychedelicNewsWire (PNW)

WednesdayAug 17, 2022 9:30 am

Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF

Company entered scientific research agreement with UCSF in June 2021 to study psilocybin effects on various inflammatory conditions Silo Pharma (OTCQB: SILO), recently announced that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients as part of a scientific research agreement (“SRA”) entered with Silo in June, 2021 to “to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. “Successful dosing and collection of blood samples from enrolled patients is an important milestone that demonstrates the progress being made…

TuesdayAug 16, 2022 2:48 pm

Important Clinical Trials That May Result in Psychedelic Legalization

Initial studies have found that certain psychedelics have plenty of potential as treatments for mental health conditions such as post-traumatic stress disorder (PTSD) and major depressive disorder. Furthermore, activists across the country have put forth a variety of measures to decriminalize psychedelics, with cities such as Denver moving to decriminalize all psychedelics. But before psychedelics can be approved for widespread medical use, they will have to go through the clinical trial system successfully. This process involves three phases: phase I trials where animals are used to test the efficacy and safety of drugs; phase 2 trials involving several dozen patients…

MondayAug 15, 2022 1:16 pm

Second Psychedelics Initiative Fails to Qualify for Colorado Ballot

Psychedelic enthusiasts, activists and researchers in Colorado will be sad to know that there won’t be two measures to legalize psychedelics on the November ballot. Two separate campaigns have pushed their own psychedelic measures since the start of the year, with only one campaign managing to collect enough signatures to qualify for the ballot. In late July, activists behind the Natural Medicine Health Act submitted around 100,000 signatures to the secretary of state’s office. The measure wants to legalize the possession of specific psychedelics, seal the records of people with prior psychedelic convictions and create a framework for psilocybin treatments.…

FridayAug 12, 2022 2:06 pm

Psilocybin Lawsuit Filed in Canada May Boost Global Psychedelics Reform Efforts

Canada banned psychedelics more than 30 years ago, outlawing the production, sale and use of psychedelics, including psilocybin, for decades. Most countries around the world followed suit and banned psychedelics. However, psychedelic drugs were still quite popular despite being prohibited due to their mind-altering effects. In recent years, this mainstream popularity has reached an explosive level, especially regarding psychedelics' ability to treat mental health conditions, resulting in a surge in psychedelic research. A new psilocybin lawsuit in Canada now has the potential to spur a wave of psychedelics reform not only in Canada but in the United States as well.…

ThursdayAug 11, 2022 12:59 pm

Five Great Podcasts for Those Interested in Psychedelics

Psychedelics have experienced a renaissance in recent years as public and scientific interest in mind-altering drugs has grown. Now researchers across the country are running studies to determine whether psychedelics have medical potential, specifically their ability to treat mental health conditions such as major depressive disorder and post-traumatic stress disorder (PTSD). Research into psychedelics is a relatively new and exciting field that is predicted to play a major role in mental health treatments over the next decade. Furthermore, given how popular these mind-altering drugs are among the mainstream public and the scientific community, there are plenty of credible media sources…

WednesdayAug 10, 2022 2:34 pm

Leading Neuroscientist Explains How Psychedelics Alters the Brain

We have seen interest in psychedelics grow significantly these last few years as more studies into the therapeutic potential of the substance has been conducted. Psychedelics are substances that alter the function of an individual’s brain when ingested. This may result in changes in their mood, perception and cognitive processes. Common psychedelics include mescaline, psilocybin, ayahuasca and peyote. Despite the fact that humans have known about and used these hallucinogens for millennia, there is still a lot we are uncertain about when it comes to these substances and how they can benefit us. Below, we look at what we’ve learned…

TuesdayAug 09, 2022 1:59 pm

Compass Pathways to Begin New Phase 2 Psychedelic Trial for Anorexia

Compass Pathways PLC (NASDAQ: CMPS) is a mental health care company that is focused on improving patient access to evidence-based innovation in mental health. The company’s stock, which trades as CMPS on the NASDAQ has been performing well, with many attributing this positive performance to the appointment of a new CEO. The company recently announced that it would be launching a new phase 2 trial on the use of its COMP360 formulation in treating anorexia. The company will conduct the trial at various prestigious research institutions in the United States and the United Kingdom, including Columbia University’s Irving Medical Center,…

MondayAug 08, 2022 2:31 pm

Toronto Firm Receives First Federal Government Funding to Study Psilocybin

After decades of prohibition, Canada is finally opening the door to psychedelic research. Canada banned psychedelics nearly 50 years ago, outlawing the production and use of psychedelic drugs such as psilocybin, the main psychoactive agent in magic mushrooms, and making it nearly impossible to research these drugs. However, the winds have been shifting in favor of psychedelics in recent years as more people have begun using them to address mental health conditions including (PTSD) and major depressive disorder. A Toronto-based company has now received Canada’s first-ever federal government funding to run a study on the impact of psilocybin on depression.…

FridayAug 05, 2022 10:42 am

Legislators in San Francisco File Initiative to Locally Decriminalize Psychedelics

Last week, legislators in San Francisco filed a measure to locally decriminalize psychedelics such as ayahuasca and psilocybin. The resolution, which also calls for broader statewide reform, was sponsored by Supervisors Hillary Ronen and Dean Preston. The measure’s enactment by the Board of Supervisors would make the city of San Francisco the largest in the country by population to deprioritize the enforcement of laws that prohibit entheogenic substances. The “whereas” section of the proposal talks about the traditional role that psychedelics play as catalysts for profound experiences of spiritual and personal growth, as well as the therapeutic potential of these…

ThursdayAug 04, 2022 12:55 pm

Three Clinical Trials On Psychedelic Microdosing Worth Following

As more research on the therapeutic benefits of psychedelics is conducted, concerns about whether microdosing works continue to grow, as many believe that the supposed benefits may be solely because of the placebo effect. It doesn’t help that data from placebo-controlled trials is inconclusive, which only means that the best way to find out whether microdosing is actually effective is to carry out properly controlled microdosing clinical trials. The following are a few of the ongoing microdosing clinical trials. Filament Health’s psilocybin clinical trial Earlier in the year, Filament Health announced that it was launching a phase II psilocybin microdosing…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050